IndustryCompany release

Voyager Technologies Q3 revenue climbs 124% to $89M; full-year outlook raised

🇺🇸 Voyager Technologies, Inc./TX (VOYG) · Mon 02 Nov 2026

The space and defence group reported a $55.7M net loss and a $742M backlog, and its only life-sciences item is new ISS biopharmaceutical research contracts.

Voyager Technologies (NYSE: VOYG), a space and defence technology company, reported third-quarter 2026 results on 2 November 2026. Revenue rose 124% year on year to $89 million.

Backlog reached $742 million, of which $347 million came from the Astrobotic acquisition. The company recorded a net loss of $55.7 million for the quarter.

Voyager raised the low end of its 2026 revenue guidance by $10 million. The full-year sales outlook now stands at $285 million to $305 million.

The release is not about a drug or biologic. Its only life-sciences element is a set of new biopharmaceutical research mission contracts for the International Space Station. The summary available gives no further detail on the contracts, such as the customers, the products involved or their value.

What it means for your team

  • No regulatory, pharmacovigilance or quality action arises from this release; it is a corporate earnings announcement.
  • Teams with an interest in microgravity research may want to track the ISS biopharmaceutical contracts, though no details have been disclosed in the material reviewed.
  • Any future use of space-based research data in development programmes would be a matter for sponsors and regulators to assess case by case.

Company's press release (SEC filing): Voyager Technologies, Inc./TX ↗

Article written by VigiEye from the official source (Voyager Technologies, Inc./TX). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →